This Is MS Multiple Sclerosis Community: Knowledge & Support

I posted this in the CCSVI forum with no replies, so maybe posting here is more suitable:

Hi,

I have CCSVI and other venous conditions

- IJV's are stenosed as they enter the chest
- May Thurner
- Poorly developed Lumbar Veins (Hypoplasia)


And i have been taking the following Vitamins/Supplements every day:
Calcium - 800mg
Magnesium - 650mg
Zinc - 75mg
Copper - 2mg
Potassium - 100mg
Fish oil (omega3) - 3000mg
Vit B50
Vit B12 - 1000 ug
Vit C - 1000mg
Vit D3 - 5000 IU
Vit E - 400 IU
Selenium - 200mcg
Beta Caretene - 15mg

Half of these are taken at midday and the other half in the evening.
I also taker a 75mg Aspirin and 0.50mg Propecia (Finasteride) (for hair loss) every morning.



So i was wondering if any of these vitamins/supplements/meds are bad for CCSVI/MT/poorly developed lumbar veins ?
or not necessary to take

Am i missing any vitamins/minerals/supplements that can help with my CCSVI/MT/Lumbar veins ?


thank you

You may want to add PYCNOGENOL. 50 mg three times a day to your supplement list.

It also lowers MMP-9s. raises HDL and helps control diabetis(sic) prvents blindness, treats hemmeroids etc etc etc lots more info on PubMed and Medlars(plus)

jackD

Phytomedicine. 2000 Oct;7(5):383-8.

PYCNOGENOL in chronic venous insufficiency.

Petrassi C, Mastromarino A, Spartera C.

Cattedra e Scuola di Specializzazione in Chirurgia Vascolare, Dipartimento di Scienze Chirurgiche, Università degli Studi di L'Aquila, Italy. chirvasc@cc.univaq.it

Abstract
The aim of out study was to investigate the efficacy of Pycnogenol - a French maritime pine bark extract - in the treatment of chronic venous insufficiency (CVI).

The study consisted of a double-blind phase - in which 20 patients were recruited and randomly treated with placebo or Pycnogenol (100 mg 2 3/day for 2 months) - and an open phase - in which other 20 patients were treated with Pycnogenol at the same dose schedule. In total, 40 patients were enrolled; 30 of them were treated with Pycnogenol and 10 with placebo.

Pycnogenol significantly improved the legs' heaviness and subcutaneous edema; the venous pressure was also significantly reduced by the Pycnogenol treatment, thus adding further clinical evidence to its therapeutic efficacy in patients with CVI.

Pycnogenol was effective, probably by either stabilizing the collagenous subendothelial basal membrane or scavenging the free radicals, or by a combination of these activities.

Clinically, capillary leakage, perivascular inflammation and subcutaneous edema were all reduced.

The safety of use of Pycnogenol is demonstrated by the lack of side effects or changes in blood biochemistry and hematologic parameters.

Pycnogenol can be therefore recommended both for prevention and treatment of CVI and related veno-capillary disturbances.

PMID: 11081989 [PubMed - indexed for MEDLINE]